Skip to main content
. Author manuscript; available in PMC: 2019 Jul 19.
Published in final edited form as: Steroids. 2018 Oct 21;140:159–166. doi: 10.1016/j.steroids.2018.10.008

Fig. 1.

Fig. 1.

Shown are plots of mean change in Relative Fluorescence Units (RFU’s) from baseline and standard deviation for 11 efficacy biomarkers in AAV and JDM. Significance is noted as follows: *P-value ≤0.05; **P-value ≤0.01; ***P-value ≤0.001. Eight of 11 biomarkers reached significance in AAV; 10 of 11 reached significance in JDM (by paired t-test). All biomarkers were decreased by glucocorticoids, except for Protein C. These changes were in the same direction as seen in previous studies in IBD and DMD [13,14]. Abbreviations: AAV = anti-neutrophil antibody-associated vasculitis; JDM = juvenile dermatomyositis; IBD = Inflammatory Bowel Disease; DMD = Duchenne muscular dystrophy; MMP-12 = matrix metalloproteinase-12; MDC = macrophage derived cytokine; PROC = Protein C; IL22-BP = IL22 binding protein; LY9 = T lymphocyte antigen Ly9; FGG = fibrinogen gamma chain; ANGPT2 = angiopoietin-2; IGFBP-2 = insulin-like growth factor binding protein-2; ITGA1 ITGB1 = integrin A1 B1.